3-Bromopyruvate: A new targeted antiglycolytic agent and a promise for cancer therapy

S. Ganapathy-Kanniappan, M. Vali, R. Kunjithapatham, M. Buijs, L. H. Syed, P. P. Rao, S. Ota, B. K. Kwak, R. Loffroy, J. F. Geschwind

Research output: Contribution to journalArticle

Abstract

The pyruvate analog, 3-bromopyruvate, is an alkylating agent and a potent inhibitor of glycolysis. This antiglycolytic property of 3-bromopyruvate has recently been exploited to target cancer cells, as most tumors depend on glycolysis for their energy requirements. The anticancer effect of 3-bromopyruvate is achieved by depleting intracellular energy (ATP) resulting in tumor cell death. In this review, we will discuss the principal mechanism of action and primary targets of 3-bromopyruvate, and report the impressive antitumor effects of 3-bromopyruvate in multiple animal tumor models. We describe that the primary mechanism of 3-bromopyruvate is via preferential alkylation of GAPDH and that 3-bromopyruvate mediated cell death is linked to generation of free radicals. Research in our laboratory also revealed that 3-bromopyruvate induces endoplasmic reticulum stress, inhibits global protein synthesis further contributing to cancer cell death. Therefore, these and other studies reveal the tremendous potential of 3-bromopyruvate as an anticancer agent.

Original languageEnglish (US)
Pages (from-to)510-517
Number of pages8
JournalCurrent Pharmaceutical Biotechnology
Volume11
Issue number5
DOIs
StatePublished - Sep 20 2010

Keywords

  • 3-Bromopyruvate
  • Alkylating agent
  • Anti-metabolite
  • GAPDH
  • Glycolysis

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of '3-Bromopyruvate: A new targeted antiglycolytic agent and a promise for cancer therapy'. Together they form a unique fingerprint.

  • Cite this

    Ganapathy-Kanniappan, S., Vali, M., Kunjithapatham, R., Buijs, M., Syed, L. H., Rao, P. P., Ota, S., Kwak, B. K., Loffroy, R., & Geschwind, J. F. (2010). 3-Bromopyruvate: A new targeted antiglycolytic agent and a promise for cancer therapy. Current Pharmaceutical Biotechnology, 11(5), 510-517. https://doi.org/10.2174/138920110791591427